Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

The clinical success of radiolabeled somatostatin analogs in the diagnosis and therapy—“theranostics”—of tumors expressing the somatostatin subtype 2 receptor (SST<sub>2</sub>R) has paved the way for the development of a broader panel of peptide radioligands targeting different human tum...

Full description

Bibliographic Details
Main Authors: Berthold A. Nock, Panagiotis Kanellopoulos, Lieke Joosten, Rosalba Mansi, Theodosia Maina
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmaceuticals
Subjects:
peptide theranostics
radiotheranostics
receptor antagonist
somatostatin radioligands
radiolabeled BBN-analogs
gastrin radioligands
Online Access:https://www.mdpi.com/1424-8247/16/5/674

Internet

https://www.mdpi.com/1424-8247/16/5/674

Similar Items